Your CEO should be strong.
Your CTO should be wise.
Your COO should be wicked, cunning, of mysterious origins, fluent in the dark arts, blurry in pictures,
We’re bringing new capabilities to GPT-Rosalind, a model series purpose-built for life sciences research at enterprise scale.
It brings GPT-5.5’s agentic coding and tool use together with stronger intelligence for drug discovery, analysis, design, and experimental workflows.
https://t.co/SrAJ3Mt7ka
Looking forward to speaking at OpenAI Forum in a week on how I leveraged ChatGPT to find cancer treatment options after doctors said there was nothing left for me to do.
https://t.co/iO26Nizrym
The Rosie story is AI doing the *information* work. Humans still ran the lab.
Now imagine when agents close that loop.
(Also the biotech pile-on is very predictable and quite boring. Good for Rosie, and the optimists are on the right side of history.)
this is actually insane
> be tech guy in australia
> adopt cancer riddled rescue dog, months to live
> not_going_to_give_you_up.mp4
> pay $3,000 to sequence her tumor DNA
> feed it to ChatGPT and AlphaFold
> zero background in biology
> identify mutated proteins, match them to drug targets
> design a custom mRNA cancer vaccine from scratch
> genomics professor is “gobsmacked” that some puppy lover did this on his own
> need ethics approval to administer it
> red tape takes longer than designing the vaccine
> 3 months, finally approved
> drive 10 hours to get rosie her first injection
> tumor halves
> coat gets glossy again
> dog is alive and happy
> professor: “if we can do this for a dog, why aren’t we rolling this out to humans?”
one man with a chatbot, and $3,000 just outperformed the entire pharmaceutical discovery pipeline.
we are going to cure so many diseases.
I dont think people realize how good things are going to get
Today, we're announcing @join_EF's Series D: $200M of fresh capital, at a unicorn+ valuation.
We're in a golden age of entrepreneurship. More individuals than ever before are taking the leap, with the world's most transformative technology at their fingertips.
For over a decade, we've backed extraordinary people without asking what idea they're working on. We call this Talent Investing; believing in someone from Day 1 and giving them the peer group, environment, and capital to find their life's work.
And it works! Companies built through EF are now worth $16bn, up from $3bn at our last raise in 2021.
Thank you to our investors for their continued belief, the EF team for bringing this vision to life, and the founders who rejected the status quo to build globally important companies with us.
And, of course, a huge thank you to @matthewclifford, my exceptional cofounder.
Robust benchmarks are the foundation on which progress in AI is built. Benchmarks for science, in particular, are extremely hard to build, but good ones are important to move the field forward.
This is a great piece from Science today, which charts progress in building new benchmarks for science: https://t.co/9A8JDQocGe
💥 Today we’re introducing Prism—a free, AI-native workspace for scientists to write and collaborate on research, powered by GPT-5.2.
Accelerating science requires progress on two fronts:
1. Frontier AI models that use scientific tools and can tackle the hardest problems
2. Integrating that AI into the products scientists use every day
Prism is free to anyone with a ChatGPT account, with unlimited projects and collaborators.
Try it today at https://t.co/cmEsJYRtW9—would love to hear your feedback.
The UK is a great country with an extraordinary history. Our stagnation is real, but it's fixable and worth fixing.
Enjoyed giving this talk at @lfg_uk last week and so encouraged by the optimistic responses I've had from people who are building a brilliant future for Britain 🚀